Table 2. Response outcomes of patients... | American Society of Hematology

Table 2.

Response outcomes of patients with NPM1-mutated MDS based on type of therapy

Response	Total (N = 28)*	Chemotherapy (n = 10)*	HMAs (n = 18)*	OR (95% CI)	P
ORR	25 (89)	10 (100)	15 (83)	0.83 (0.68-1.0)	.533
PD	3 (11)	0 (0)	3 (17)	0.83 (0.68-1.0)	.533
HI	3 (11)	0 (0)	3 (17)	0.78 (0.61-0.99)	.265
mCR†	7 (25)	1 (10)	6 (33)	0.22 (0.2-2.2)	.364
PR	2 (7)	0 (0)	2 (11)	0.89 (0.75-1.0)	.524
CR	14 (50)	9 (90)	5 (28)	23.4 (2.3-235.5)	.004

Response	Total (N = 28)*	Chemotherapy (n = 10)*	HMAs (n = 18)*	OR (95% CI)	P
ORR	25 (89)	10 (100)	15 (83)	0.83 (0.68-1.0)	.533
PD	3 (11)	0 (0)	3 (17)	0.83 (0.68-1.0)	.533
HI	3 (11)	0 (0)	3 (17)	0.78 (0.61-0.99)	.265
mCR†	7 (25)	1 (10)	6 (33)	0.22 (0.2-2.2)	.364
PR	2 (7)	0 (0)	2 (11)	0.89 (0.75-1.0)	.524
CR	14 (50)	9 (90)	5 (28)	23.4 (2.3-235.5)	.004

HI, hematological improvement; mCR, marrow CR; OR, odds ratio; PD, progressive disease; PR, partial response.

Data are n (%).

Two patients had mCR with hematological improvement without meeting the criteria for CR.